A 6 month, open label, prospective, multi centre, international study of a transition to flexibly dose paliperidone palmitate (a second generation antipsychotic) in patients with schizophrenia previously unsuccessfully treated with oral or long acting injectable antipsychotics

Trial Profile

A 6 month, open label, prospective, multi centre, international study of a transition to flexibly dose paliperidone palmitate (a second generation antipsychotic) in patients with schizophrenia previously unsuccessfully treated with oral or long acting injectable antipsychotics

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms PALMFlexS
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 04 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record and as per European Clinical Trials Database record, status is ongoing in Spain and UK and completed in remaining countries, hence status amended as per NCT.
    • 16 Aug 2012 Actual patient number changed from 1046 to 1045 as reported by ClinicalTrials.gov.
    • 07 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top